Shares of XBiotech Inc. (NASDAQ:XBIT) were down 6% during mid-day trading on Monday . The stock traded as low as $14.27 and last traded at $14.50, with a volume of 170,470 shares traded. The stock had previously closed at $15.42.

A number of equities analysts recently commented on XBIT shares. Noble Financial reissued a “buy” rating and set a $24.00 price target on shares of XBiotech in a research note on Thursday, May 19th. Zacks Investment Research raised XBiotech from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Tuesday, May 24th.

The company’s 50-day moving average price is $16.10 and its 200 day moving average price is $12.79. The stock’s market capitalization is $467.78 million.

In other news, Director W Thorpe Mckenzie purchased 20,000 shares of the stock in a transaction on Thursday, May 26th. The stock was bought at an average price of $13.96 per share, with a total value of $279,200.00. Following the transaction, the director now owns 3,898,600 shares in the company, valued at approximately $54,424,456. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.